ZCA
RETA

Zeke Capital Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Zeke Capital Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,056
Closed -$216K – 525
2019
Q4 		$216K Buy
+1,056
New +$193K 0.02% 517

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Zeke Capital Advisors's RETA Position: Q1 2020 in Review

Zeke Capital Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2020, closing a stake of 1,056 shares — an estimated $216K sold.

Zeke Capital Advisors first reported a position in RETA in Q4 2019 and held it in 1 quarter. The position peaked at $216K in Q4 2019. 214 funds tracked by Wall St. Rank hold RETA as of Q1 2020.

  • Zeke Capital Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2020 after selling out during the quarter.
  • Zeke Capital Advisors sold 1,056 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2020, an estimated $216K.
  • Zeke Capital Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 1 quarter.
  • Zeke Capital Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $216K in Q4 2019.
  • 214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2020.

Based on Zeke Capital Advisors's 13F filing for Q1 2020, filed 24 Apr 2020.